Spain
· Delayed Price · Currency is EUR Biotechnology Assets Statistics
Total Valuation
Biotechnology Assets has a market cap or net worth of EUR 19.76 million. The enterprise value is 23.33 million.
| Market Cap | 19.76M |
| Enterprise Value | 23.33M |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotechnology Assets has 63.74 million shares outstanding.
| Shares Outstanding | 63.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.11% |
| Float | 35.78M |
Valuation Ratios
The trailing PE ratio is 11.37.
| PE Ratio | 11.37 |
| Forward PE | n/a |
| PS Ratio | 4.58 |
| PB Ratio | 2.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.27, with an EV/FCF ratio of -1,067.89.
| EV / Earnings | 14.82 |
| EV / Sales | 5.97 |
| EV / EBITDA | 6.27 |
| EV / EBIT | 8.61 |
| EV / FCF | -1,067.89 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 63.31.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | 63.31 |
| Debt / EBITDA | 1.11 |
| Debt / FCF | -189.33 |
| Interest Coverage | 8.71 |
Financial Efficiency
Return on equity (ROE) is 30.25% and return on invested capital (ROIC) is 14.85%.
| Return on Equity (ROE) | 30.25% |
| Return on Assets (ROA) | 9.65% |
| Return on Capital (ROIC) | 14.85% |
| Revenue Per Employee | 105,633 |
| Profits Per Employee | 42,534 |
| Employee Count | 37 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +97.91% in the last 52 weeks. The beta is 1.39, so Biotechnology Assets's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | +97.91% |
| 50-Day Moving Average | 0.32 |
| 200-Day Moving Average | 0.37 |
| Relative Strength Index (RSI) | 49.85 |
| Average Volume (20 Days) | 27,594 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotechnology Assets had revenue of EUR 3.91 million and earned 1.57 million in profits. Earnings per share was 0.03.
| Revenue | 3.91M |
| Gross Profit | 3.46M |
| Operating Income | 2.71M |
| Pretax Income | 2.32M |
| Net Income | 1.57M |
| EBITDA | 3.72M |
| EBIT | 2.71M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 416,868 in cash and 4.14 million in debt, giving a net cash position of -3.72 million or -0.06 per share.
| Cash & Cash Equivalents | 416,868 |
| Total Debt | 4.14M |
| Net Cash | -3.72M |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | 6.53M |
| Book Value Per Share | 0.12 |
| Working Capital | 147,778 |
Cash Flow
In the last 12 months, operating cash flow was 47,734 and capital expenditures -69,577, giving a free cash flow of -21,843.
| Operating Cash Flow | 47,734 |
| Capital Expenditures | -69,577 |
| Free Cash Flow | -21,843 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 88.47%, with operating and profit margins of 69.28% and 40.27%.
| Gross Margin | 88.47% |
| Operating Margin | 69.28% |
| Pretax Margin | 59.42% |
| Profit Margin | 40.27% |
| EBITDA Margin | 95.23% |
| EBIT Margin | 69.28% |
| FCF Margin | -0.56% |
Dividends & Yields
Biotechnology Assets does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 8.79% |
| FCF Yield | -0.11% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |